Apogee Therapeutics (APGE) Return on Capital Employed (2023 - 2026)
Apogee Therapeutics (APGE) reported Return on Capital Employed of 6.78% for Q1 2026, up 223.0% year-over-year from 2.1% in Q1 2025, and up 4.84% on a QoQ basis from 7.12% in Q4 2025.
Apogee Therapeutics (APGE) has 4 years of Return on Capital Employed data on file, last reported at 6.78% in Q1 2026.
- Quarterly Return on Capital Employed rose 223.0% year-over-year to 6.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.78% (up 223.0% YoY) and the FY2025 annual result came in at 6.56%, up 40.0% from the prior year.
- Return on Capital Employed rose to 6.78% in Q1 2026 per APGE's latest filing, from 7.12% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 4.48% in Q4 2023 and bottomed at 26.76% in Q3 2023.
- The 4-year median for Return on Capital Employed is 8.68% (2024), against an average of 10.93%.
- The widest annual swing landed in 2024, when Return on Capital Employed soared 1316 bps; it then slumped 540 bps in 2025.
- Tracing APGE's Return on Capital Employed over 4 years: stood at 4.48% in 2023, then slipped by 16 bps to 5.19% in 2024, then slumped by 37 bps to 7.12% in 2025, then climbed by 5 bps to 6.78% in 2026.
- Per Business Quant, the three latest APGE Return on Capital Employed figures stand at 6.78% (Q1 2026), 7.12% (Q4 2025), and 17.24% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | -6.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.78% |
| Dec 31, 2025 | -7.12% |
| Sep 30, 2025 | -17.24% |
| Jun 30, 2025 | -14.09% |
| Mar 31, 2025 | -9.01% |
| Dec 31, 2024 | -5.19% |
| Sep 30, 2024 | -13.60% |
| Jun 30, 2024 | -8.68% |
| Mar 31, 2024 | -7.30% |
| Dec 31, 2023 | -4.48% |
| Sep 30, 2023 | -26.76% |